Phosphorylated α-synuclein at serine residue 129 decreased in Parkinson’s disease patients taking 250mg of daily niacin for six months
Objective: The main objective was to determine if α-synuclein could be modulated by niacin supplementation, contributing to improved Parkinson’s disease (PD) symptoms. Background: Niacin supplementation…A Phase 1b study to test the safety, pharmacokinetics, and pharmacodynamics of a novel inflammasome inhibitor in early-stage Parkinson’s disease: Rationale and study design
Objective: To describe the study design of a Phase 1b to test the safety, pharmacokinetics, and pharmacodynamics of a novel inflammasome inhibitor in individuals with…4 YEARLONG POST PARTUM AUTOIMMUNE CHOREA AS INITIAL PRESENTATION OF INCOMPLETE SLE/APS
Objective: The aim is to report a case of a 4 yearlong postpartum autoimmune chorea secondary to incomplete SLE/APS. Background: Chorea is a movement disorder…Inflammatory microglial and astroglial phenotype associated with pathological alpha-synuclein inclusions in the substantia nigra
Objective: To characterize neuroinflammatory gene expression in microglia and astrocytes associated with early alpha-synuclein (a-syn) inclusion formation. Background: Parkinson’s disease (PD) is characterized by alpha-synuclein…Alteration of the fecal microbiota in Turkish patients with idiopathic Parkinson’s disease
Objective: To determine whether the gut microbiota is altered in Turkish patients with Parkinson Disease (PD) and the potential effect of gut microbiota on pre-motor…In-vivo measurement of tau depositions in anti-IgLON5 disease with 18F-PI2620-PET
Objective: The aim of the study was to examine the potential of the second-generation tau-PET tracer 18F-PI2620 to detect tau deposition in anti-IgLON5 disease. Background:…Movement disorders with phosphodiesterase 10A IgG autoimmunity
Objective: To report four new cases of phosphodiesterase 10A (PDE10A) IgG neurological autoimmunity. Background: PDE10A IgG was recently identified as a biomarker of paraneoplastic neurological…IMPACT OF COVID 19 ON PARKINSON’S DISEASE: A CROSS SECTIONAL STUDY
Objective: To review the impact of Covid 19 on symptoms and signs of Parkinsons as well as general being in patients with Parkinson’s Disease at…Characterising Natural Killer cells in early Parkinson’s disease
Objective: To determine whether the number and phenotype of Natural Killer (NK) cells in the blood is altered in early Parkinson’s disease (PD). Background: Accumulating…Mortality in Parkinson’s patients following Covid19 infection in the second wave of the pandemic
Objective: To analyze causes of mortality and death certification in Parkinson’s disease patients who had SARS- CoV2 in Reading, West Berkshire, United Kingdom (UK) Background:…
- « Previous Page
- 1
- …
- 10
- 11
- 12
- 13
- 14
- …
- 25
- Next Page »